

Datasheet: HCA374 BATCH NUMBER 165519

Description:	HUMAN ANTI SECUKINUMAB (DRUG/TARGET COMPLEX)
Specificity:	SECUKINUMAB DRUG/TARGET COMPLEX
Other names:	Cosentyx
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD36948ia
lsotype:	lgG1
Quantity:	0.1 mg

Product Details

Applications	This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit <u>www.bio-rad-antibodies.com/protocols</u> .					
		Yes	No	Not Determined	Suggested Dilution	
	ELISA	-				
	Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.					
Product Form	Human IgG1 antibody (kappa light chain) selected from the HuCAL phage display library and expressed in a human cell line. This antibody is supplied as a liquid.					
Preparation	Purified IgG prepared by	affinity chr	omatogra	aphy on Protein A		
Source	HKB-11					
Buffer Solution	Phosphate buffered saline					
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)					
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml					
Immunogen	Secukinumab/IL-17A complex					

Specificity	Human Anti-Secukinumab (Drug/Target Complex) Antibody, clone AbD36948ia specifically recognizes the human monoclonal antibody drug secukinumab when in complex with its target, interleukin 17A (IL-17A). The antibody does not recognize free secukinumab or unbound IL-17A. It can be used to measure levels of secukinumab or its biosimilars in patient samples.					
	Clone AbD36948ia is a complex specific, non-inhibitory fully human IgG1 format antibody that can be used to develop a pharmacokinetic (PK) antigen capture assay to measure free secukinumab that has been captured via immobilized IL-17A.					
	Protocol: <u>PK antigen capture ELISA</u>					
	Secukinumab (Cosentyx) is a human IgG1/kappa antibody generated using transgenic mouse technology. It has been approved for the treatment of plaque psoriasis, ankylosing spondylitis, psoriatic arthritis and non-radiographic axial spondyloarthritis. Secukinumab inhibits interleukin 17A (IL-17A) produced mainly by inflammatory T helper 17 cells (Lubrano and Perrotta 2016).					
	View a summary of all anti-secukinumab antibodies					
Affinity	The intrinsic affinity of the monovalent form of Human anti Secukinumab antibody, clone AbD36948ia is $K_D = 5$ nM as measured by real time, label free molecular interaction analysis on immobilized hIL-17A/secukinumab complex.					
ELISA	Clone AbD36948ia is recommended for use as the detection reagent in an antigen capture assay to measure free secukinumab captured on immobilized IL-17A.					
	Protocol: PK antigen capture ELISA					
Storage	This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.					
	Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.					
Guarantee	12 months from date of despatch					
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details. Cosentyx is a trademark of Novartis.					
Health And Safety Information	Material Safety Datasheet documentation #10040 available at: https://www.bio-rad-antibodies.com/SDS/HCA374 10040					
Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro					

	testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.		
Regulatory	For research purposes only		
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual.		

Related Products

Recommended Useful Reagents

HUMAN ANTI SECUKINUMAB (HCA370) HUMAN ANTI SECUKINUMAB (HCA371) HUMAN ANTI SECUKINUMAB (HCA372) HUMAN ANTI SECUKINUMAB (HCA373) HUMAN ANTI SECUKINUMAB (DRUG/TARGET COMPLEX) (HCA375) HISPEC ASSAY DILUENT (BUF049A) LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK002P)

North & South	Tel: +1 800 265 7376	Worldwide	Tel: +44 (0)1865 852 700	Europe	Tel: +49 (0) 89 8090 95 21			
America	Fax: +1 919 878 3751		Fax: +44 (0)1865 852 739		Fax: +49 (0) 89 8090 95 50			
	Email: antibody_sales_us@bio-ra	d.com	Email: antibody_sales_uk@bio-rad.com		Email: antibody_sales_de@bio-rad.com			
To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M422432:230911'								

Printed on 18 Jan 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint